Biohaven Pharmaceutical Holding Co Ltd

Biohaven Pharmaceutical — Investor Presentation (January 2020)

71 slides from Biohaven Pharmaceutical's investor presentation, Jan 13, 2020

  1. Slide 1: Neuro Innovation: Meeting Patient Needs. Growing Value.

    NYSE: BHVN © 2019 Biohaven Pharmaceuticals Inc. All rights reserved. NEURO INNOVATION Meeting Patient Needs. Growing Value. INVESTOR PRESENTATION | JANUARY 2020

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward - looking statements within the meaning of “safe harbor” provisions of The Private Securities L itigation Reform Act of 1995, including: statements about Biohaven Pharmaceutical Holding Company Ltd. (The ”Company”) and our plans to develop and commercial

  3. Slide 3: At Biohaven, We Demand More for Patients

    At Biohaven, We Demand More for Patients. Meeting patient needs. Growing value. GOALS Launch rimegepant 1Q2020 Three marketed drugs by 2021 – 2022 Grow while maintaining a lean, efficient, high - performing culture ELLIE Rimegepant clinical trial participant for more than 2 years

  4. Slide 4: Late Stage Development Pipeline

    JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 4 Rimegepant : formerly BHV - 3000; Vazegepant : formerly BHV - 3500; MPO: Myeloperoxidase; TDP - 43: TAR DNA - binding protein 43; UC1MT: monoclonal antibody targeting extracellula r metallothionein Late Stage Development Pipeline Pre - Clinical Amyotroph

  5. Slide 5: Advanced the Portfolio in 2019, Transitioning to Commercialization in 2020

    Advanced the Portfolio in 2019, Transitioning to Commercialization in 2020 JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 5 Rimegepant • Filed NDA for acute migraine • Positive Phase 3 results • NEJM, Lancet • Completed enrollment of Phase 3 for prevention Vazegepant • Positive Phase 2/3 results with f

  6. Slide 6: CGRP-Antagonist Platform: Redefining the Treatment of Migraine

    CGRP - Antagonist Platform: Redefining the Treatment of Migraine

  7. Slide 7: Oral CGRP Receptor Antagonists Developed to Address Unmet Needs

    CGRP receptor CGRP Trigeminal nerve Central Glial cell Peripheral 1. Edvinsson L et al (2018). Nat Rev Neurol 14(6): 338 - 350. 2. Raddant AC et al (2011). Expert Rev Mol Med 13:e36. 3. Conway CM et al (2018). Headache 58(8):1295. 4. Data on file. Biohaven Pharmaceuticals. • CGRP is a peptide releas

  8. Slide 8: Multiple Approaches for Acute & Preventive Treatment of Migraine

    Multiple Approaches Targeted for Acute & Preventive Treatment of Migraine JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 8 NO JECTION™ CGRP Drug Delivery Platform 1. Exclusive World - Wide License with Catalent for use of Zydis ® Fast Dissolve Technology in our migraine product candidates 2. Aptar Phar

  9. Slide 9: Rimegepant ODT and Tablet NDAs

    RIMEGEPANT ODT AND TABLET NDAS Rimegepant FDA Late - Cycle Communication Update (December 5, 2019) JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 9 Remaining Review Plans • Finalize reviews • Conduct labeling negotiations • Finalize post - marketing commitments No Substantive Review Issues Identified i

  10. Slide 10: Rimegepant: Three Positive Phase 3 Trials, 1-Year Safety

    OVER 3,700* SUBJECTS TREATED AND >113,000 RIMEGEPANT DOSES DELIVERED TO DATE Rimegepant: Three Positive Phase 3 Trials, 1 - Year Safety 1. Lipton, R. B., et al. (2019). " Rimegepant , an Oral Calcitonin Gene - Related Peptide Receptor Antagonist, for Migraine." N Engl J Med 381(2): 142 - 149. 2. Cro

  11. Slide 11: Rimegepant ODT: Preparing to Redefine Relief

    Rimegepant 75 mg ODT: Preparing to Redefine Relief JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 11 In clinical trials, the safety and tolerability profile of rimegepant was similar to placebo FAST Dissolves in seconds and starts working in minutes LASTS Single dose demonstrated sustained efficacy acr

  12. Slide 12: Rimegepant ODT: Rapid Relief and Durable Effects with Single Dose

    Rimegepant 75 mg ODT: Rapid Relief and Durable Effects with Single Dose JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 12 Croop R et al. Lancet. 2019;394(10200):737 - 745. Rapid Relief 2 - Hour Effects Durable Benefit (2h – 48h) FROM 2 – 24 HOURS POST DOSE • Sustained pain relief • Sustained freedom fr

  13. Slide 13: Rimegepant 1-Year Long-Term Safety Study Design

    Rimegepant 1 - Year Long - Term Safety to Capture Real World Patient Usage JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 13 SCREENING/ BASELINE Patients Received Free Access to Daily Supply 1 of Rimegepant for 1 year TREATMENT PERIOD up to 52 Weeks END of Treatment or Early D/C Visit 30 - day Observat

  14. Slide 14: Median Monthly Usage Under 8 Pills/Month with PRN Dosing

    • PRN protocol allowed dosing up to once per calendar day Median Monthly Usage: < 8 pills/month over 1 - Year with PRN Dosing Rimegepant 75 mg Tablets Treated Subjects Average rimegepant exposure [tablets per 4 weeks] PRN Dosing 2 – 8 cohort {attack history/ mo } (n=1031) PRN Dosing 9 – 14 cohort {a

  15. Slide 15: Rimegepant Reduced Total Migraine Disability (MIDAS) by ~50%

    Rimegepant demonstrated improvements in mean change from baseline by ~50% for total MIDAS over the course of 1 - year Rimegepant Reduced Total Migraine Disability (MIDAS) by ~50% in 1 - Year Study 33.9 20.7 19.1 17.5 16.4 15 17 19 21 23 25 27 29 31 33 35 0 weeks 12 Weeks 24 Weeks 36 Weeks 52 weeks M

  16. Slide 16: Rimegepant Reduces Lost Productivity Time by Approximately 50%

    Significant improvements in absenteeism and presenteeism items were seen throughout treatment follow - up Rimegepant 75 mg Up to Once Daily Reduces Lost Productivity Time by Approximately 50% Mean Item Score Week Absenteeism Days of missed work, school, household, social or leisure activities due to

  17. Slide 17: Rimegepant Long-Term Safety Study 201 Interim Analysis

    RIMEGEPANT LONG - TERM SAFETY – STUDY 201, INTERIM ANALYSIS 21FEB2 019 48.4% of subjects in the EOD+PRN cohort during month 3 achieved ≥50% reduction from baseline of moderate - to - severe migraine days per month with rimegepant 75 mg (n=244) Rimegepant Shows Reduction in Moderate - to - Severe Mig

  18. Slide 18: Vazegepant: First Third-Generation Intranasal CGRP Receptor Antagonist

    FIRST INTRANASAL FORMULATION OF A SMALL MOLECULE CGRP RECEPTOR A NTAGONIST Vazegepant : First and Only Third - Generation, Intranasal CGRP Receptor Antagonist • Superior chemical attributes • Potent antagonist at the human CGRP receptor • Highly soluble and high free fraction • US composition of mat

  19. Slide 19: Vazegepant Phase 2/3 Study BHV3500-201

    VAZEGEPANT PHASE 2/3 — STUDY BHV3500 - 201, 10MG & 20MG INTRANASAL Vazegepant 10 mg and 20 mg Demonstrated Early Separation From Placebo at 15, 60 and 120 Minutes, Durable Through 24 – 48 Hours 1. Pain Relief is defined as patients who have either mild - pain or no - pain during the specified interv

  20. Slide 20: Commercial and Launch Readiness

    Commercial and Launch Readiness

  21. Slide 21: Migraine Significantly Impairs Patients' Lives

    Migraine Significantly Impairs Patient’s Lives JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 21 References: 1. Burch R, Rizzoli P, Loder E. Headache . 2018;58(4):496 – 505. 2. The American Headache Society. Headache . 2019;59(1):1 – 18. 3. Bonafede M, Cai Q, Capell K. JMCP . 2017;23(11):1169 – 1176. 4

  22. Slide 22: Migraine Attacks: A Leading Cause of Economic Burden in US

    Migraine Attacks: A Leading Cause of Economic Burden in US JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 22 References: 1. The American Headache Society. Headache . 2019;59(1):1 - 18. 2. Migraine Resource Center website. https://www.mdedge.com/neurology/ migraineresourcecenter /article/160613/headache

  23. Slide 23: Low Patient Satisfaction and High Abandonment of Current Acute Treatments

    Patients Report Low Satisfaction With Current Acute Treatments and High Abandonment Rates Across the Spectrum of Therapies JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 23 References: . 1. Migraine.com. https://migraine.com/infographic/migraine - is - more - than - a - headache - its - a - life - ache

  24. Slide 24: Oral CGRP Receptor Antagonists Address Needs Unmet by Triptans

    Oral CGRP Receptor Antagonists Address Treatment Needs Unmet by Triptans JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 24 References: Lipton RB et al. Headache. 2017;57:1026 - 40. Perry CM et al. Drugs. 1998;55:889 - 922. Cortelli P et al. Neurol Sci. 2011;32 Suppl 1:S95 - 8. Derry CJ et al. Cochrane

  25. Slide 25: Triptans, NSAIDs and Opioids Comparison

    Triptans NSAIDs Opioids Examples Sumatriptan, naratriptan, zolmitripta n 1 Diclofenac, ketoprofen, flurbiprofe n 2,3 Butorphanol, morphine, hydromorphon e 2,5 Migraine - specific treatment? Ye s 1 N o 3 N o 6 Use • Moderate or severe attacks O R 2 • Mild - to - moderate that respond poorly to NSAIDs

  26. Slide 26: Reyvow (Lasmiditan): Serotonin 1F Receptor Agonist

    ABUSE POTENTIAL Controlled substance schedule pending CNS DEPRESSION, SEROTONIN SYNDROME & MEDICATION OVERUSE HEADACHES (detoxification may be necessary) DRIVING IMPAIRMENT Advise patients not to drive for 8 hours REYVOW™ ( Lasmiditan ): Serotonin (5 - HT) 1F Receptor Agonist JANUARY 2020 BIOHAVEN I

  27. Slide 27: Rimegepant Launch Readiness Objectives

    RECRUIT TOP TALENT STRATEGICALLY INVEST BUILD LAUNCH CAPABILITIES ESTABLISH CULTURE OF ACCOUNTABILITY EFFICIENT, INNOVATIVE, MODERN DAY LAUNCH Rimegepant Launch Readiness Objectives JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 27

  28. Slide 28: Rimegepant Launch Readiness Marketing Across Relevant Channels

    Rimegepant Launch Readiness Marketing Across Relevant Channels JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 28 Social Search Cross Screen V ideo Disease State Awareness Campaign Branded Launch Campaign

  29. Slide 29: Rimegepant Launch Readiness: Clinical Presentation Penetration

    ALL PRIORITY ACCOUNTS BY LIVES Rimegepant Launch Readiness: Clinical Presentation Penetration JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 29 All Targeted Accounts Total Lives % Total All Accounts Completed 182,000,082 75.4% Scheduled 39,321,353 16.3% Not Yet Scheduled 19,923,412 8.3% Total 241,244,8

  30. Slide 30: Glutamate Platform: Therapies for Neurologic and Neuropsychiatric Indications

    GLUTAMATE PLATFORM Therapies for Neurologic and Neuropsychiatric Indications

  31. Slide 31: The Role of Glutamate: Present in 90% of Brain Synapses

    NORMAL FUNCTION Healthy State JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 31 The Role of Glutamate: Present in 90% of Brain Synapses EXCITOTOXICITY Diseased State AMYOTROPHIC LATERAL SCLEROSIS SPINOCEREBELLAR ATAXIA DEMENTIA NEURODEGENERATION NEUROTOXICITY SEIZURES DEPRESSION ANXIETY STRESS CANCER P

  32. Slide 32: Glutamate Mechanisms of Action in CNS

    JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 32 Glutamate Mechanisms of Action in CNS Glutamate Transporter Modulation • Troriluzole Glutamate NMDA Receptor Antagonism • BHV - 5000 Third - party clinical trials provide basis for exploration of troriluzole and BHV - 5000 in multiple neurologic and neu

  33. Slide 33: Unmet Medical Need in ALS

    UNMET MEDICAL NEED IN ALS Riluzole ( Rilutek ® ) is approved for the treatment of patients with amyotrophic lateral sclerosis (ALS) and proven to extend survival • Originally marketed by Sanofi, received FDA approval in 1995 • In 2013, the FDA approved the first generic versions of riluzole • Doses

  34. Slide 34: Troriluzole: Rational Drug Discovery to Optimize Therapy

    JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 34 Troriluzole: Rational Drug Discovery to Optimize Therapy • Improved absorption • Enhanced bioavailability • Reduced drug burden • Reduced first pass metabolism • Favorable safety profile • Once - daily dosing

  35. Slide 35: Peptide Transporter Enhances Absorption of Troriluzole

    JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 35 Peptide Transporter 1 Enhances Absorption of Troriluzole PepT1 PepT1 = Peptide Transporter 1 ACTIVE ABSORPTION IN INTESTINAL TRACT BY PEPT1

  36. Slide 36: Troriluzole: Targeted Lead-Indication Development Strategy

    Social Anxiety Disorder Generalized Anxiety Disorder Bipolar Depression JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 36 Troriluzole: Targeted Lead - Indication Development Strategy * = Third - party study / collaboration ongoing or planned (ADCS Collaboration for AD; ET Study Group Collaboration for

  37. Slide 37: Generalized Anxiety Disorder: Disease Overview

    • Lifetime prevalence approximately 4% in the US 1 • Typically chronic 2 • Low remission rate ~50% 3 • Symptoms characterized by • Excessive anxiety and worry • Associated with restlessness, easy fatigue, difficulty concentrating, irritability, tension, and sleep disturbance • Unmet medical need • O

  38. Slide 38: Riluzole Preclinical Models

    RILUZOLE PRECLINICAL MODELS • Riluzole efficacious in multiple preclinical models (elevated plus maze, the light - dark test, open field test) 1 • Riluzole enhances recognition memory and facilitates extinction of fear response 2 • Benzodiazepine - like efficacy without cognitive impairment 3 Glutam

  39. Slide 39: Riluzole Open-Label Trial in Generalized Anxiety Disorder

    • Single center, open - label, fixed dose study • 18 subjects with GAD • Administered riluzole 50 mg BID for 8 weeks • Primary endpoint HAM - A (Hamilton Anxiety Scale) • Results • 15 patients completed trial • 12 responders • 8 remitters • Mean HAM - A decreased from 20.0 at baseline to 7.5 at week

  40. Slide 40: Objective Biomarkers Correlate with Improvement

    JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 40 • Improvement in anxiety strongly correlated with increased hippocampal NAA (marker for neuronal function) 1,2 • Increases precede therapeutic benefit • Increases in hippocampus volume observed in remitters 3 — that correlate with improvement Objective

  41. Slide 41: Yale POC Study: Anti-Anxiety Effects of BHV-0223

    BHV - 0223 DESIGN • Double - blind, placebo controlled crossover trial with two Impromptu Speech Task sessions • Subjects diagnosed with Social Anxiety Disorder • N=22 randomized (21 completed) • BHV - 0223 vs PBO, dosed 1 hour prior to public speaking stress task; separated by two to ten days to al

  42. Slide 42: Yale Human POC Study Consistent With Preclinical Models

    RILUZOLE PRECLINICAL Yale Human POC Study Is Consistent With Preclinical Models Showing Riluzole’s Anti - Anxiety Effects and Enhancement of Recognition Memory Sugiyama et al 2017 (Brain Behavioral Research) Anti - Anxiety Effects %Time Spent in Open Arm Saline Riluzole Enhances Recognition Memory D

  43. Slide 43: Troriluzole Phase 2/3 GAD Trial Design

    • Multicenter (US only), randomized, double - blind, placebo - controlled trial in outpatients with GAD • Troriluzole 100 mg vs Placebo BID*, N=372 • Primary Outcome: Change on HAM - A from baseline to Week 8 TRORILUZOLE (BHV - 4157) Phase 2/3 GAD TRIAL DESIGN * BID: twice daily Troriluzole 100 mg B

  44. Slide 44: Pathological Features of Alzheimer's Disease

    • Brain atrophy • Neuronal cell death • Amyloid and tau pathology • Synapse loss (most highly correlated with clinical symptoms) • Glial cell dysfunction Pathological Features of Alzheimer’s Disease Congdon Nat Rev Neurol. 2018;14(7):399 - 415 JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 44

  45. Slide 45: Glutamate Transporter (GLT-1) Is Reduced in Human AD Brains

    JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 45 Glutamate Transporter (GLT - 1) Is Reduced in Human AD Brains Human autopsy observations from AD and controls (n=13) GLT - 1 immunoreactivity in temporal neocortex area in AD is significantly weaker than that in control A. Hosi et al. Neuropathology and

  46. Slide 46: Riluzole Rescues Symptoms, Function and Pathology in AD Animal Models

    Increases GLT - 1 Glutamate Transporter 4 JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 46 Riluzole Rescues Symptoms, Function and Pathology in AD Animal Models 1. Pereira Proc Natl Acad Sci 2014; 2.Hunsberger J Neurochem 2015; 3. Hunsberger, Metab Brain Dis 2016; 4. Pereira Molecular Psychiatry 2017;

  47. Slide 47: Troriluzole Phase 2/3 Clinical Trial Design in AD

    TRORILUZOLE (BHV - 4157) PHASE 2/3 • Key entry criteria • Diagnosis of mild to moderate Alzheimer’s disease with Mini - Mental State Exam (MMSE) score of 14 – 24 • Co - primary efficacy endpoints • Alzheimer's Disease Assessment Scale (ADAS) - Cog11 • Clinical Dementia Rating - Sum of Boxes (CDR - S

  48. Slide 48: Cerebellar Ataxias

    Cerebellar Ataxias JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 48 • Characterized by: • Poor balance with falls • Dysarthria / dysphagia • Incoordination of limbs • Cognitive impairment • Postural or kinetic tremor • Oculomotor dysfunction • Spinocerebellar ataxia (SCA; >40 subtypes) • Affects 1 – 5

  49. Slide 49: Troriluzole Study in Spinocerebellar Ataxia vs Natural History Cohort

    JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 49 • Post - hoc analysis of patients enrolled in long - term extension of Phase 2b/3 troriluzole SCA trial • Primary efficacy endpoint: change from baseline in the Total SARA Score after 48 weeks • Patients from BHV4157 - 201 trial versus eligibility crite

  50. Slide 50: Troriluzole Study BHV4157-206 Randomized Controlled Trial in SCA

    Key Entry Criteria • SCA genotypes ( SCA1, SCA2, SCA3, SCA6, SCA7, SCA8, SCA10) Design • Sample size: 230 subjects • Randomization: 1:1 • Stratification: by SCA genotype • Dose: Troriluzole 200 mg QD vs. Placebo QD • Primary Outcome: Modified SARA Scale • FDA aligned outcome measure Status • Phase 3

  51. Slide 51: OCD Treatments Are Limited and Need Is Vast

    JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 51 • Few FDA - approved treatments • Serotonin reuptake inhibitors (SSRIs and clomipramine) are the only approved monotherapy • No new mechanisms for 30 years • With limited efficacy • <50% of patients respond well • 25 – 30% are refractory • Many of those

  52. Slide 52: Accumulating Evidence for Glutamatergic Dysfunction in OCD

    JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 52 Accumulating Evidence for Glutamatergic Dysfunction in OCD GENES ANIMAL MODELS NEURAL NETWORKS PATIENTS IN THE CLINIC Genetic association studies: Glutamate transporter gene (SLC1A1 on chromosome 9p24) associated w/OCD 1 GWAS studies are focusing attent

  53. Slide 53: Neurochemical Evidence for Glutamate Dysregulation in OCD

    JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 53 Neurochemical Evidence for Glutamate Dysregulation in OCD Rosenberg et al. 2000 Consistent with pathologic hyperactivity in cortico - striatal circuit Suggests clinical testing of agents that enhance glutamate uptake Healthy Control Subjects n = 11 Trea

  54. Slide 54: Neurochemical Evidence for Glutamate Dysregulation in OCD (CSF)

    JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 54 Neurochemical Evidence for Glutamate Dysregulation in OCD Consistent with pathologic hyperactivity in cortico - striatal circuit Suggests clinical testing of agents that enhance glutamate uptake CSF Glutamate Concentrations Bhattacharyya et al. 2009

  55. Slide 55: Randomized Controlled Trial with Riluzole Augmentation

    • Outpatients with moderate - to - severe OCD severity (Y - BOCS score ≥ 21) and free of medication treatment for at least six weeks • Randomized to receive fluvoxamine (up to 200 mg/day) plus either placebo or riluzole (50 mg twice daily) • Robust benefit on primary outcome measure (change in Y - B

  56. Slide 56: Troriluzole Study BHV4157-202 in OCD

    KEY ENTRY CRITERIA • Moderate - to - severe OCD and inadequate response to standard of care DESIGN • Sample size: 226 subjects • Randomization: 1:1 • Dose: Troriluzole 200 mg QD vs. Placebo QD (in patients on standard of care) • Primary Outcome: Y - BOCS, a precedented outcome measure accepted by FD

  57. Slide 57: MPO Platform: Therapies for Neuroinflammation

    MPO PLATFORM Therapies for Neuroinflammation

  58. Slide 58: Verdiperstat for Neuroinflammation: Multiple System Atrophy

    VERDIPERSTAT (BHV - 3241) FOR NEUROINFLAMMATION • Rare, rapidly progressive and fatal neurodegenerative disease • Prevalence: 2 – 5 per 100,000 • Clinical symptoms • Parkinsonism: characteristic tremor (not responsive to L - DOPA), rigidity, dysarthria, falls • Cerebellar ataxia • Autonomic failure:

  59. Slide 59: BHV-3241 for Neuroinflammation: MPO Inhibitor

    BHV - 3241 FOR NEUROINFLAMMATION • Myeloperoxidase (MPO) enzyme • Key mediator of oxidative and inflammatory processes that lead to neurodegeneration • Promotes alpha - synuclein aggregation • Increased in human MSA brains in areas of neurodegeneration 1 • Verdiperstat • Potent, first - in - class,

  60. Slide 60: Verdiperstat Neuroprotective Effects in MSA Animal Model

    BHV - 3241 FOR NEUROINFLAMMATION Verdiperstat Neuroprotective Effects in MSA Animal Model 1 Reduces GCIs of alpha - synuclein Promotes functional (motor) improvements Suppresses microglial activation RLZ treated Rescues neurodegeneration 1. Neurotox Res 2012;21(4):393 - 404 JANUARY 2020 BIOHAVEN INV

  61. Slide 61: Verdiperstat Clinical Experience

    BHV - 3241 FOR NEUROINFLAMMATION • Studied in approximately 250 subjects (healthy volunteers, Parkinson’s disease, MSA) • Generally safe and well tolerated • Demonstrated target engagement (↓ blood MPO activity) • Reduced neuroinflammation (microglial activation) in Parkinson’s disease • Positron Em

  62. Slide 62: Verdiperstat Phase 2 Study in MSA

    BHV - 3241 FOR NEUROINFLAMMATION • Phase 2 study: randomized double - blind controlled trial • N=61 subjects (MSA - C, 34; MSA - P, 24) • Randomized to 12 weeks treatment • Placebo BID vs BHV - 3241 300 mg BID vs BHV - 3241 600 mg BID • Outcome measures: UMSARS*, PET, safety (labs, AE’s, ECGs, vital

  63. Slide 63: Verdiperstat Plan for Phase 3 Study in MSA

    BHV - 3241 FOR NEUROINFLAMMATION DESIGN • Sample size: 252 subjects • Randomization: 1:1 • Dose: 600 mg BID vs. Placebo *based on Ph2 • Primary outcome measure: Unified MSA Rating Scale • Sites: US, EU (UK, FR, GER, AUS, IT), CHINA STATUS • FDA EOP2 Meeting completed • EU Scientific Advice received

  64. Slide 64: Metallothionein Blockade: A Novel Anti-Inflammatory Therapeutic

    METALLOTHIONEIN BLOCKADE A Novel Anti - Inflammatory Therapeutic

  65. Slide 65: Metallothionein Can Alter Immune Response

    Metallothionein Can Alter Immune Response by Influencing Cellular Trafficking Healthy tissue Stress - causing cell damage Metallothionein production and release as a “danger signal” Extracellular MT recruits inflammatory cell Disease propagation cycle: more stress and more inflammation JANUARY 2020

  66. Slide 66: Metallothionein: A Novel Target in the Immune Cascade

    Metallothionein: A Novel Target in the Immune Cascade • Metallothionein (MT) is an intracellular protein in non - stressed conditions • MT is released from cells/tissues that are stressed, damaged, or killed • Extracellular MT can act as a pro - inflammatory agent • MT acts as an agent of disease pr

  67. Slide 67: UC1MT Reduces Inflammation in Adoptive T Cell Transfer Model of IBD

    UC1MT Reduces Inflammation in the Adoptive T Cell Transfer Model of IBD Anti - MT performance exceeded conventional anti - TNF therapeutic JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 67

  68. Slide 68: UC1MT: First in Class Metallothionein Antagonist

    UC1MT: First in Class Metallothionein Antagonist for a Novel Pro - Inflammatory Target • UC1MT is a high affinity monoclonal antibody that recognizes both mouse and human MT1 and MT2 • Confirmed the role of MT involvement in multiple disease models with better activity than anti - TNF • Evidence of

  69. Slide 69: 2020 Milestones/Commercial Transformation

    2020 Milestones/Commercial Transformation

  70. Slide 70: 2020 Milestones & Next Steps

    2020 Milestones & Next Steps JANUARY 2020 BIOHAVEN INVESTOR PRESENTATION 70 4Q20/ 1Q21 Phase 2/3 trial data of troriluzole in Alzheimer’s Disease 1Q20 Phase 2/3 topline data of troriluzole in OCD 1Q20 Phase 2/3 topline data of troriluzole in GAD ALS: amyotrophic lateral sclerosis, AD: Alzheimer’s Di

  71. Slide 71: Neuro Innovation

    NEURO INNOVATION WWW.BIOHAVENPHARMA.COM Zydis ® is a registered trademark of Catalent. Rilutek ® is a registered trademark of Covis Pharma B.V. Reyvow is a trademark of Eli Lilly and Company NYSE: BHVN © 2019 Biohaven Pharmaceuticals Inc. All rights reserved.

Biohaven Pharmaceutical Holding — Investor Presentation (January 2020) on 6ix